PRTA
Companies
NASDAQ
Prothena Corporation plc
Health Care
$5.75
-$8.10 (-58.48%)
Price Chart
Overview
About PRTA
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Market Cap
$1.1B
Volume
3.4M
Avg. Volume
2.9M
P/E Ratio
-2.4372091
Dividend Yield
1.91%
Employees
160.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.91
High Correlation
Volatility
High (0.78)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, PRTA shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$1.1B
Volume3.4M
P/E Ratio-2.44
Dividend Yield1.91%
Important Dates
Next Dividend
Next Earnings
February 21, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025